Table 6.

Study outcomes for phase 3 trial

Outcome	Dextromethorphan- bupropion (n =156)	Placebo (n = 162)	Difference
Overall change from baseline at week 6 in MADRS total scorea	−15.9 ± 0.9	−12.0 ± 0.9	−3.9 (1.4, −6.4)d,*
Change from baseline in MADRS total score, week 1a	−7.2 ± 0.6	−5 ± 0.6	−2.2 (−0.6, −3.9)d,*
Change from baseline in MADRS total score, week 2a	−11.1 ± 0.7	−7.7 ± 0.7	−3.4 (−1.4, −5.5)d,*
Remission at week 2b	24 (16.9)	12 (7.5)	9.4 (1.9, 16.8)e,*
Remission at week 6b	49 (39.5)	26 (17.3)	22.2 (11.7, 32.7)e,*
Clinical response at week 2c	40 (28.2)	27 (17.0)	11.2 (1.8, 20.6)e,*
Clinical response at week 6c	67 (54.0)	51 (34.0)	20 (8.4, 31.6)e,*

Values are presented as least-squares mean ± standard error or number (%).

^aMADRS: Montgomery-Åsberg Depression Rating Scale; 10-item clinician-rated questionnaire with scores ranging from 0−60. A higher score corresponds to more severe depression. ^bRemission defined as MADRS total score ≤ 10. ^cClinical response defined as ≥ 50% reduction in MADRS total score from baseline. ^dLeast-squares mean (95% confidence interval). ^e% (95% confidence interval).

*p < 0.05.